AnalystBook Research · Company Intelligence

CVRx, Inc.

CVRXNasdaq

Built from CVRx, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

CVRx, Inc.: Revenue grew 10.4% to $56.65M from $51.29M. Net loss narrowed to $53.31M from $59.97M. Free cash flow outflow widened to $40.75M from $40.51M. Operating margin expanded 2549 bps to -90.49%. CVRx, Inc.'s annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context; the earnings-quality screen is grey.

The read at a glance✓ Audited against SEC data
  • GrowthRevenue grew 10.4% to $56.65M from $51.29MOK
  • ProfitabilityNet loss narrowed to $53.31M from $59.97MOK
  • Cash flowFree cash flow outflow widened to $40.75M from $40.51MWatch
  • MarginsOperating margin expanded 2549 bps to -90.49%OK
  • AccountingDistress-range screen needs contextWatch
  • Insiders2 purchases and 11 salesOK

Business

Autonomic activation is also a significant mechanism involved with multiple other cardiovascular diseases, such as hypertension, angina pectoris and cardiac arrhythmia, as well as other diseases, such as chronic kidney disease. ​ 8 The role of the imbalance of ANS in HF ​ The ANS, which is a PART of the peripheral nervous system, plays a vital role in the function of the heart.

Leadership changes

From CVRx, Inc.'s own filings, the day they're filed.

  • Kevin Ballinger · directors · appointmenteff. 2024-09-03
  • Ali Behbahani · director · departureeff. 2024-09-03
  • Kevin Hykes · President · appointmenteff. 2024-02-12

Latest filings

  • 8-K · Company announcement2026-08-11
  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-08-06
  • 8-K · Company announcement2026-06-09
  • 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about CVRx, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.